Biophytis Initiates Phase 2 OBA Clinical Trial for Obesity Treatment

Biophytis SA, a biotechnology firm specializing in treatments for age-related diseases, has confirmed the launch of its Phase 2 OBA clinical trial targeting obesity. The study aims to evaluate the efficacy and safety of their drug candidate, BIO101, in countering muscle strength loss induced by GLP-1 agonists in obese patients. The trial is scheduled to commence in early 2025.

Following a capital increase of €2.6 million and promising preclinical outcomes, Biophytis is poised to advance its clinical studies. The U.S. FDA's Investigational New Drug clearance in July 2024 marked a significant step for the OBA program. The initiative leverages the expertise of Professor Marc-André Cornier in the obesity domain.

The company is actively seeking a pharmaceutical partner to facilitate the subsequent clinical development and market launch in North America.